Although these data do not provide a direct link to tumor immunity, they collectively demonstrate that pharmaceutical compounds targeting DYRK1B could potentially intervene not only in the cancer cell compartment but also in its microenvironment. This evidence concerns the gene DYRK1B and cancer.